L-carnosine

L-Carnosine: A Comprehensive Encyclopedic Reference

1. Identity: Chemical Names, Structure, and Physical Properties

L-Carnosine is a naturally occurring dipeptide composed of two amino acids joined by a peptide bond. It was discovered in 1900 as an abundant non-protein nitrogen-containing compound of meat. Also referred to as β-alanyl-L-histidine or L-carnosine, it is a naturally occurring dipeptide having the molecular formula C₉H₁₄N₄O₃ and possessing a molecular weight of 226.236 g/mol.

L-carnosine is a dipeptide which consists of β-alanine linked to L-histidine via a peptide bond. In its isolated form, L-carnosine is a tasteless, odorless, readily water-soluble white crystalline powder, and its pH in aqueous solution is in the range of 8.0 to 8.5.

Most animals, except humans, also possess a methylated variant of carnosine, either anserine or ophidine/balenine, collectively called the histidine-containing dipeptides. These related compounds share several biological properties with L-carnosine but differ in their resistance to enzymatic degradation.

Common Preparations and Supplement Forms

L-carnosine is commercially available in several forms. Oral supplements are most commonly supplied as encapsulated or tableted powder. L-carnosine is naturally occurring and can be isolated from the muscle tissue of various species of vertebrates. For pharmaceutical and supplement manufacturing, synthetic routes are also widely employed. L-carnosine can be synthesized by reacting β-alanine with a halogenated aromatic alcohol to give a β-alanine ester derivative, which is then reacted with histidine methyl ester to produce a dipeptide ester; β-alanyl-L-histidine (L-carnosine) is finally obtained by hydrolysis of the ester.

An ophthalmic prodrug form, N-acetylcarnosine (NAC), has been studied as eye drops. When applied as an eye drop, L-carnosine itself cannot penetrate the eye; however, when applied to the surface of the eye, N-acetylcarnosine (NAC) penetrates the cornea into the front chamber of the eye (near to where the cataract is), where it is metabolized into L-carnosine.

2. Natural Sources and Endogenous Distribution

Carnosine is a naturally occurring dipeptide, neuropeptide found in the brain, stomach, kidneys, olfactory bulbs, cardiac muscles, and in abundant amounts in skeletal muscles. It is particularly abundant in the brain and skeletal muscle of mammals, and levels are higher in muscles with glycolytic metabolism.

Dietary sources of L-carnosine are exclusively animal-based. The predominant source of dietary carnosine in humans is via meat and fish consumption; in particular, beef, pork, chicken, and tuna are good sources, although it should be noted that cooking practices significantly influence the amount available. The top food sources of carnosine are meats such as turkey, chicken, beef, or pork; other animal products such as eggs, milk, and cheese contain carnosine, but only in trace amounts.

Cooked ground beef has been measured to contain approximately 124 mg of carnosine per 100 g. Given the diversity of the human diet, the potential range of dietary carnosine intakes are relatively broad and might range from 50 to 500 mg per day in the omnivorous diet. Conversely, vegetarians have been shown to have significantly lower muscle carnosine levels than their meat-eating counterparts.

3. Historical Discovery and Early Use

Carnosine is a biologically active dipeptide discovered by Russian scientists; the history of its discovery refers back to the early twentieth century, particularly to the experiments of V. S. Gulevich, a well-known Russian biochemist. In his studies of nitrogen contents in samples of minced meat, Gulevich noticed that the total content of organic nitrogen was significantly greater than the sum of protein nitrogen and nitrogen of all extracted components of muscular tissue known at that time; he suggested that there were unidentified nitrogen-containing compounds in muscular tissue, and later managed to isolate these compounds from muscle extract.

Because this substance was isolated from minced meat, it was given the name "carnosine" (from the Latin term caro, carnis — meat). The discovery of the presence of carnosine in muscle dates back to more than one hundred years ago, while the definition of its chemical structure can be traced to the early 1920s.

A variety of biological effects of carnosine were demonstrated in patients by Russian physiologists and physicians before World War II, and Russian researchers not only discovered carnosine but also used it in clinical practice — the first medicinal form based on this dipeptide. This medicinal form was developed at the Institute of Physiotherapy in Kharkov, clinically tested in the 1930s, and studies demonstrated therapeutic efficiency of carnosine in the treatment of infectious and rheumatic polyarthritis, and peptic ulcer.

In 1938, scientists discovered carnosine as an important intracellular pH buffer in the muscle; when we exercise, highly reactive hydrogen ions cause a fall in pH in muscles, a process also referred to as acidification. Carnosine was found to have a perfect pKa value with the best buffering capacity for ideal physiological conditions.

L-carnosine does not feature prominently in traditional herbal medicine systems such as Ayurveda, Traditional Chinese Medicine, or Western herbalism, as it is an endogenous dipeptide rather than a plant-derived compound. Its clinical and therapeutic investigation has been almost entirely a product of twentieth-century biochemical and pharmacological research, originating chiefly in Russian and Soviet scientific institutions before expanding globally from the 1980s onward.

4. Key Constituents and Established Mechanisms of Action

4.1 Biosynthesis

Carnosine is synthesized by bonding of the amino acids β-alanine (which plays a regulatory function) and L-histidine (which confers biological activity), a reaction catalyzed by the enzyme carnosine synthase. β-alanine becomes available by hepatic breakdown of thymidine, uracil, and dietary dipeptides obtained from meat consumption and is considered to be a non-proteinogenic, rate-limiting precursor of carnosine. L-histidine, on the other hand, is an essential amino acid present in serum and serves as a proteinogenic precursor with bioactive properties.

Studies have shown that the chronic oral ingestion of β-alanine can substantially elevate, by up to 80%, the carnosine content of human skeletal muscle, which is the major production and storage site for carnosine in the human body. Inadequate vitamin B6 intake has also been shown to lower cardiac and skeletal muscle carnosine levels.

4.2 pH Buffering

Carnosine supports physiological homeostasis by buffering intracellular pH, chelating metals, and conjugating with and neutralizing toxic aldehydes such as acrolein. During high-intensity exercise, hydrogen ions accumulate in muscle tissue and lower intracellular pH, leading to fatigue. High concentrations of carnosine reduce the level of acidity in the muscles; by safeguarding against lactic acid buildup, carnosine improves muscle elasticity and delays or prevents muscle fatigue.

4.3 Antioxidant Activity

Carnosine (beta-alanyl-L-histidine) is a natural imidazole-containing compound found in the non-protein fraction of mammalian tissues. Due to a combination of weak metal chelating activity and hydroxyl and lipid peroxyl radical scavenging, as well as reducing activities toward liberated fatty acid and phospholipid hydroperoxides, carnosine appears to be a physiological antioxidant able to efficiently protect the lipid phase of biological membranes and aqueous environments.

4.4 Anti-Glycation Activity

Carnosine can inhibit advanced glycation end-product (AGE) and advanced lipoxidation end-product (ALE) formation by detoxifying reactive carbonyl species through its imidazole ring. Carnosine has been proven useful in preventing the reactivity of methylglyoxal (MGO) and glyoxal, which are carbonyl compounds that can produce protein glycation and aggregation. Carnosine most likely interacts with reactive carbonyl intermediate compounds such as glyoxal and methylglyoxal to inhibit the formation of advanced glycated end products.

Carnosine can act as an advanced lipoxidation end-product inhibitor through the following mechanisms: (1) inhibiting lipid oxidation and breakdown to reactive carbonyl species; (2) detoxifying reactive carbonyl species; and (3) reacting with carbonylated proteins ("carnosinylation").

4.5 Metal Ion Chelation

Carnosine's biochemical properties include pH-buffering, metal-ion chelation, and antioxidant capacity, as well as the capacity to protect against formation of advanced glycation and lipoxidation end-products. By chelating transition metals such as copper and zinc, carnosine can prevent these ions from catalyzing oxidative damage to proteins and lipids.

4.6 Anti-Inflammatory Activity

Carnosine is a naturally occurring endogenous dipeptide composed by the ligation of β-alanine and L-histidine, performed particularly by tissues with increased oxidative metabolism such as muscles and brain; over the last 50 years, different studies have assessed its role and function through numerous in vitro, in vivo, and clinical studies, demonstrating a multimodal mechanism of action including anti-aggregant, antioxidant, and anti-inflammatory activities.

4.7 Carnosinase and Bioavailability

A critical issue for the clinical application of orally administered L-carnosine is its rapid degradation in the body. Carnosine and related compounds are not degraded by regular (di)peptidases, but their metabolism is characterized by its own hydrolytic enzymes named carnosinases; carnosinase was first described by Hanson and Smith in 1949 from swine kidney, and two forms have since been molecularly identified as CN1, or serum carnosinase, and CN2, or tissue carnosinase.

In humans, after oral consumption and absorption into circulation, carnosine is rapidly hydrolyzed by serum carnosinase (CN1), resulting in a short half-life of approximately 1.20 ± 0.36 minutes. Carnosine uptake from the gut is mediated by the proton-dependent peptide transporter PepT1; it is subsequently hydrolyzed within the enterocyte by tissue carnosinase (CN2) or transported intact into the blood where it is hydrolyzed by serum carnosinase (CN1) into its substituents β-alanine and L-histidine.

However, some of the ingested carnosine can localize in skeletal muscle, and studies have shown that skeletal muscle levels doubled in humans receiving carnosine supplements; in addition to skeletal muscle, ingested carnosine can enter red blood cells, where it is prevented from degradation by CN1.

After beef consumption, carnosine is detected in plasma within 15 minutes, reaching a maximum after 3.5 hours, whereas 5.5 hours after carnosine consumption, carnosine concentrations fall below detectable serum values.

5. Scientific Evidence by Area of Use

5.1 Exercise Performance and Skeletal Muscle

The most extensively studied and best-supported application of L-carnosine relates to its role in skeletal muscle physiology and exercise performance. Carnosine, traditionally used in exercise physiology to increase exercise performance, has potential preventative and therapeutic benefits in obesity, insulin resistance, type 2 diabetes and diabetic microvascular and macrovascular complications, as well as a number of neurological and mental health conditions.

A total of 76 clinical trials were found using search terms "carnosine and supplementation," most of them related to carnosine muscle content and physical capacity/exercise in health. The large body of evidence here is mainly composed of studies using β-alanine (the rate-limiting precursor to muscle carnosine synthesis) rather than direct L-carnosine supplementation. Data indicate that β-alanine is the rate-limiting amino acid to muscle carnosine synthesis, a finding corroborated by supplementation studies showing that β-alanine alone is similarly effective at increasing muscle carnosine content as an equivalent dose of β-alanine delivered in carnosine (which comprises both β-alanine and histidine).

Carnosine may exert antioxidant activity and has been shown to inhibit lipid oxidation; it also seems to have the ability to buffer pH activity, and appears to delay muscle fatigue. Evidence from exercise physiology is relatively robust in demonstrating the pH-buffering role of muscle carnosine in high-intensity exercise contexts, though most intervention trials have used β-alanine supplementation as the indirect means to elevate muscle carnosine.

5.2 Diabetes and Metabolic Disease

Researchers have examined the protective role that carnosine could exert in the context of type 2 diabetes mellitus (T2DM), cardiovascular disease, and Alzheimer's disease, which share common pathogenic mechanisms including oxidative stress, inflammation, and aggregation; many lines of evidence suggest the potential therapeutic role that carnosine could exert against T2DM, being an antioxidant, anti-glycation, and anti-nitrating compound, also able to affect glycemic control and to prevent diabetic complications.

A 2023 systematic review and meta-analysis (PROSPERO-registered, 14 studies, 9 qualifying for meta-analysis) assessed L-carnosine's effect in age-related diseases. Results from the meta-analysis showed that in diabetes mellitus, HbA1c [mean difference (MD) 95% CI = −1.25 (−2.49, −0.022); p = 0.05] and fasting blood sugar [MD 95% CI = −12.44 (−22.44, −2.44); p = 0.01] showed statistically significant differences favoring the L-carnosine group over the control group. However, the high heterogeneity for HbA1c (I² = 85%) means these results should be interpreted with caution.

In animal studies, carnosine has been shown to suppress many biochemical processes that accompany aging and age-related chronic diseases such as obesity, type 2 diabetes, and diabetes complications, but only limited human data exists. Intervention studies with supplementation of carnosine targeting obesity, insulin resistance, and cardiovascular risk factors in individuals at risk of and with type 2 diabetes are necessary to investigate the putative role of carnosine in prevention and management of type 2 diabetes and cardiovascular disease.

5.3 Cardiovascular Health

To examine associations with cardiovascular disease (CVD) risk, researchers measured urinary levels of non-conjugated carnosine and its acrolein conjugates in participants of the Louisville Healthy Heart Study and found that non-conjugated carnosine was significantly associated with hypertension (p = 0.011), heart failure (p = 0.015), high CVD risk (p < 0.001), body mass index (p = 0.007), high-sensitivity C-reactive protein (p = 0.026), and high-density lipoprotein (p = 0.007). These associations are cross-sectional and do not establish causation.

Despite the fact that individual studies showed increases in exercise capacity and functional capacity, statistical significance was not found in the intervention group compared to the control group in cardiovascular studies. The overall cardiovascular evidence in humans remains preliminary, limited, and insufficiently powered.

5.4 Neurodegenerative Disorders and Cognitive Function

Carnosine is a natural endogenous molecule that has been extensively studied during recent years due to its promising beneficial effects for human health; it presents multimodal mechanisms of action, being able to exert antioxidant, anti-inflammatory, and anti-aggregate activities, among others.

In a type 2 diabetes animal model, carnosine improved cognitive deficits without affecting blood glucose levels or body weight; it enhanced antioxidant response, reduced lipid peroxidation, and modulated autophagy via activation of the Akt/mTOR pathway. However, much of the neurodegenerative disease research remains at the preclinical stage.

In the 2023 systematic review and meta-analysis: in neurodegenerative disorder, the Wechsler Memory Scale Logical Memory 2 (WMS-LM2) [MD 95% CI = 1.34 (0.83, 1.85); p < 0.00001] showed statistically significant difference favoring the L-carnosine group, while the Alzheimer's Disease Assessment Scale (ADAS) and Beck Depression Inventory (BDI) showed statistically significant differences favoring the control group over L-carnosine.

Neurodegenerative studies suggest that L-carnosine improves memory deficiencies among elderly populations in accordance with the WMS-2 scale, but otherwise failed to show significant results for other tools; it is likely that L-carnosine affects specific cognitive functions, which may be observed in the clinical setting using more specialized techniques rather than broad assessment of cognitive status.

5.5 Autism Spectrum Disorder (ASD)

L-carnosine has been proposed to have neuroprotective, antioxidant, and anti-convulsive properties that may benefit children with autism spectrum disorder.

One study in 31 children with ASD showed that eight weeks of carnosine supplementation at 800 mg daily decreased autism severity scores compared with placebo, especially on behaviour, socialization, and communication sub-scores, with improvements in receptive language and parent-reported impression of change also observed. This is in contrast with another RCT of the same duration and outcome measure in 43 children, which found no effect on autism scores, perhaps due to the use of a lower dosage of carnosine (500 mg daily).

Clinical trials of L-carnosine supplementation in children with ASD have demonstrated inconsistent results; not all studies conducted to date have reported evident improvements in social dysfunction in children with ASD following L-carnosine supplementation. The results of small-scale clinical studies have been inconsistent, with some studies showing positive effects on social and behavioral responses and others reporting no positive effects, highlighting the need for further investigations on a larger scale.

5.6 Attention-Deficit/Hyperactivity Disorder (ADHD)

Clinical studies have demonstrated that L-carnosine supplementation can improve behavioral symptoms, cognitive function, and social communication in children with ADHD and ASD; this has been explored for therapeutic effects on neurodevelopmental disorders. However, the evidence base is limited to small-scale clinical trials, and the findings require replication in larger, more rigorous trials before conclusions can be drawn.

5.7 Ophthalmic Applications: Cataracts

Cataract tends to result from oxidative stress; the protein L-carnosine is known to have an antioxidant effect on the cataractous lens, so biochemically there is sound logic for exploring L-carnosine as an agent to reverse or even prevent progression of cataract. Because direct topical L-carnosine cannot penetrate the eye, research has focused on the prodrug form N-acetylcarnosine (NAC).

Nine-month treatment with N-acetylcarnosine resulted in improved visual acuity in subjects with cataract, and glare sensitivity was improved in subjects with cataract and in non-cataract older subjects. However, results of human studies to date have been variable and unpredictable; a 2017 meta-analysis concluded there was no convincing evidence that NAC reverses cataracts or prevents their progression.

The Cochrane review on this topic concluded: it is uncertain whether NAC eye drops prevent, or reverse, the progression of cataracts.

5.8 Neuroprotection and Ischemic Stroke

Preclinical evidence has explored carnosine in ischemic stroke models. Intravenous treatment with carnosine exhibited robust cerebroprotection in a dose-dependent manner, with long clinically relevant therapeutic time windows of 6 hours and 9 hours in transient and permanent stroke models, respectively, and histological outcomes and functional improvements including motor and sensory deficits were sustained on the 14th day post-stroke onset. In safety and tolerability assessments, carnosine did not exhibit any evidence of adverse effects or toxicity; histological evaluation of organs, complete blood count, coagulation tests, and serum chemistry did not reveal any abnormalities; in primary neuronal cell cultures and ex vivo brain homogenates, carnosine exhibited robust antiexcitotoxic, antioxidant, and mitochondria-protecting activity. These findings remain at the preclinical stage; no human stroke trials have been reported.

6. Body Systems and Health Areas of Association

• Musculoskeletal system: Skeletal and cardiac muscle are the primary repositories of L-carnosine in the body. The dipeptide acts as an intracellular pH buffer, supporting sustained muscular contraction and delaying fatigue during high-intensity exercise.
• Central nervous system: Carnosine is a natural dipeptide molecule expressed in the CNS, known as β-alanyl-L-histidine, and can enter the brain from the periphery administration. It has been studied in neurodegenerative conditions including Alzheimer's disease and ischemic stroke.
• Metabolic and endocrine system: Carnosine is associated with improved glycemic control markers, anti-glycation activity, and cardiometabolic risk factor modification, particularly in diabetic states.
• Cardiovascular system: Carnosine is a regulator of intracellular calcium and contractility in cardiac muscles. Observational data link urinary carnosine metabolite profiles with cardiovascular risk indices.
• Ocular system: L-carnosine is endogenously present in the crystalline lens; depletion has been observed in cataract development, and its prodrug NAC has been explored as a topical treatment.
• Integumentary system (skin aging): The anti-glycation and antioxidant properties of carnosine have generated interest in skin aging, though formal clinical evidence in this area is sparse.
• Immune and inflammatory regulation: In vitro, in vivo, and clinical studies have demonstrated multimodal mechanisms including anti-inflammatory activities.

7. Dosage Forms and Dosages Reported in Studies

The following dosages are reported from cited studies and should not be interpreted as therapeutic recommendations.

• Oral capsules/tablets (general supplementation and aging studies): Dosages in clinical trials have ranged broadly. Most disease-focused human trials have used doses between 500 mg and 2,000 mg per day, typically in divided doses.
• ASD studies: Trials in children with ASD have used 800 mg daily (showing positive effects on behavioral subscores) and 500 mg daily (where no significant effect was observed), each administered over eight weeks.
• Single-dose escalation safety study: Oral carnosine was safe and well tolerated up to a dose of 10 g. Long-term dosing at 5 g twice daily did not result in any adverse events.
• Ophthalmic prodrug (N-acetylcarnosine eye drops): Studies have used 1% NAC lubricant eye drops, applied topically to the eye; a nine-month treatment course was used in clinical studies assessing visual acuity and glare sensitivity.
• β-alanine as indirect route: One protocol used an orally ingested dose of β-alanine starting at 4.0 g per day divided into 8 separate supplement ingestions, gradually increased to 6.4 g per day; carnosine concentrations measured in vastus lateralis biopsies were found to increase by 58.8% and 80.1% in the 4th- and 10th-week treatment groups, respectively.
• Pharmacokinetic study: After beef consumption, carnosine is detected in plasma within 15 minutes, reaching a maximum after 3.5 hours; 5.5 hours after carnosine consumption, concentrations fall below detectable serum values.

8. Safety Considerations and Interactions

8.1 General Safety Profile

L-carnosine is available as an over-the-counter food additive and appears safe in human trials. Animal toxicity studies have demonstrated a very wide safety margin. An effective anti-tumor amount of L-carnosine in mouse models is 1 mg per mouse, or 50 mg/kg; this amount corresponds to 1/181 of the acute toxicity LD50 (9,087 mg/kg) in peritoneal administration, suggesting high safety of L-carnosine.

8.2 Human Dose-Dependent Adverse Effects

At doses of 15 g, the frequency of adverse events became unacceptably high, with 77% of participants experiencing side effects, most commonly headache (43.5%), nausea (21.7%), and paraesthesia (21.7%). These findings come from a single-dose escalation study in healthy volunteers and establish an approximate upper tolerance boundary. While pharmacokinetic profiles varied between individuals, peak plasma concentrations occurred within the first hour of dosing, with little circulating carnosine detectable beyond 4 hours; brain carnosine concentration increased at 1 hour post-dose but reverted to baseline values by 5 hours; long-term dosing at 5 g twice daily did not result in any adverse events.

8.3 Carnosinase Genetic Variation and Individual Response

Carnosine is unstable in serum because of molecular hydrolysis operated by a specific enzyme — circulating carnosinase 1 (CN1). Genetic variation in the CN1 enzyme means that individual responses to L-carnosine supplementation can differ markedly, which may explain some of the inconsistency in clinical trial outcomes. Prolonged carnosinemia can be induced by carnosinase saturation in subjects with low carnosinase activity after a 4.2 ± 0.6 g carnosine acute intake.

8.4 Interactions with Vitamin B6

Inadequate vitamin B6 intake lowers cardiac and skeletal muscle carnosine levels, suggesting that vitamin B6 status is a relevant cofactor for maintaining endogenous carnosine concentrations.

8.5 Preclinical Safety Evidence

Carnosine (2000 mg/kg) did not induce signs of toxicity in any of the examined organs in preclinical rat studies. No significant differences were found between control (saline-treated) and carnosine-treated groups in body weight change or amount of food consumption, and no rats died in any group.

8.6 Evidence Quality and Limitations

Relatively little evidence is available in humans; future studies should focus on well-designed clinical trials to confirm or refute a potential role of carnosine in the prevention and treatment of chronic diseases in humans, in addition to advancing knowledge from basic science and animal studies. While carnosine emerges as a multifunctional and well-tolerated molecule, further research is needed to clarify its therapeutic relevance in human diseases.

A limited number of clinical studies related to diseases have been conducted, mostly in diabetes and/or obesity. Many of the trials that do exist are small, short in duration, and vary considerably in dosing protocols, outcome measures, and populations studied, limiting the strength of conclusions that can be drawn. For most proposed therapeutic applications outside of exercise physiology, the evidence remains preliminary.

References

• Boldyrev AA, Aldini G, Derave W. Physiology and Pathophysiology of Carnosine. Physiological Reviews. 2013;93(4):1803–1845. American Physiological Society.
• Belović M, et al. Carnosine, Small but Mighty—Prospect of Use as Functional Ingredient for Functional Food Formulation. PMC / Antioxidants. 2021.
• Caruso G, et al. The therapeutic potential of carnosine: Focus on cellular and molecular mechanisms. PMC. 2023.
• Audano M, et al. Antioxidant and Neuroprotective Effects of Carnosine: Therapeutic Implications in Neurodegenerative Diseases. PMC. 2022.
• Schön M, et al. The Potential of Carnosine in Brain-Related Disorders: A Comprehensive Review of Current Evidence. Nutrients. 2019;11(6):1196. PMC.
• Caruso G, et al. Preclinical evidence and therapeutic perspectives on carnosine for the treatment of neurodegenerative disorders. PMC. 2025.
• Kabthymer RH, et al. Effect of L-Carnosine in Patients with Age-Related Diseases: A Systematic Review and Meta-Analysis. Frontiers in Bioscience (Landmark Ed). 2023;28(1):18. PubMed.
• Kabthymer RH, et al. Effect of L-Carnosine in Patients with Age-Related Diseases: A Systematic Review and Meta-Analysis. Frontiers in Bioscience. 2023. IMR Press.
• Baye E, et al. Muscle Carnosine Is Associated with Cardiometabolic Risk Factors in Humans. PLOS ONE. 2015. PMC.
• Baye E, et al. Physiological and therapeutic effects of carnosine on cardiometabolic risk and disease. Amino Acids. 2016;48(5):1131–1149. PubMed.
• Babizhayev MA, et al. On the Anticataractogenic Effects of L-Carnosine: Is It Best Described as an Antioxidant, Metal-Chelating Agent or Glycation Inhibitor? PMC. 2016.
• Dubois VDB, et al. N-acetylcarnosine (NAC) drops for age-related cataract. Cochrane Database Syst Rev. 2017. PMC.
• Babizhayev MA, et al. N-Acetylcarnosine sustained drug delivery eye drops to control the signs of ageless vision. PMC. 2009.
• Babizhayev MA. State of the art clinical efficacy and safety evaluation of N-acetylcarnosine dipeptide ophthalmic prodrug. Curr Drug Deliv. 2009. PubMed.
• Rajanikant GK, et al. Safety and Efficacy Evaluation of Carnosine, an Endogenous Neuroprotective Agent for Ischemic Stroke. Stroke. 2013. AHA Journals.
• Ibi M, et al. Oral Supplementation with L-Carnosine Attenuates Social Recognition Deficits in CD157KO Mice via Oxytocin Release. PMC. 2022.
• Saadati S, et al. Effect of L-Carnosine in children with autism spectrum disorders: a systematic review and meta-analysis of randomised controlled trials. Amino Acids. 2021. Springer Nature.
• Evaluating Dietary Carnosine Supplementation in Healthy Human Volunteers: A Safety, Tolerability, Plasma and Brain Concentration Study. Nutrients. 2025. PMC.
• Aldini G, et al. A carnosine intervention study in overweight human volunteers: bioavailability and reactive carbonyl species sequestering effect. Scientific Reports. 2016. Nature.
• Pepper ED, et al. Antiglycation Effects of Carnosine and Other Compounds on the Long-Term Survival of Escherichia coli. Appl Environ Microbiol. 2010. PMC.
• Boldyrev AA, et al. L-carnosine (beta-alanyl-L-histidine) and carcinine (beta-alanylhistamine) act as natural antioxidants with hydroxyl-radical-scavenging and lipid-peroxidase activities. Biochemistry (Mosc). 1994. PubMed.
• de Jager S, et al. Acute balenine supplementation in humans as a natural carnosinase-resistant alternative to carnosine. PMC. 2023.
• Evaluation of supplementary carnosine accumulation and distribution: an initial analysis of participants in the Nucleophilic Defense Against PM Toxicity (NEAT) clinical trial. Amino Acids. 2024. Springer Nature.
• Stegen S, et al. Can the Skeletal Muscle Carnosine Response to Beta-Alanine Supplementation Be Optimized? Frontiers in Nutrition. 2019.
• Park YJ, et al. Quantitation of Carnosine in Humans Plasma after Dietary Consumption of Beef. J Agric Food Chem. 2005.
• Schuchardt JP, et al. Urinary Levels of the Acrolein Conjugates of Carnosine Are Associated with Cardiovascular Disease Risk. PMC. 2021.
• Karnopedia. Carnosine—History and Discovery.
• ScienceDirect. Carnosine—an overview. Agricultural and Biological Sciences.
• Xing L, et al. Carnosine—a natural bioactive dipeptide: bioaccessibility, bioavailability and health benefits. J Food Bioact. 2019. ResearchGate.